Drugs / Anti-LILRA6 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07263906 | Dec 2025 → Oct 2027 expected | acute myeloid leukemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-LILRA6 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07263906 ↗ |
| Known as | LILRA6 CAR-T cells | “This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute...” NCT07263906 ↗ |
| Modality | Cell therapy | “LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells)” NCT07263906 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT07263906 ↗ |
| Target | LILRA6 | “lentiviral vector-transducted peripheral blood-derived T cells to express anti-LILRA6 CAR” NCT07263906 ↗ |